
Opinion|Videos|March 20, 2025
Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC
Experts share high-level results from the investigation of cretostimogene grenadenorepvec, an investigational targeted immunotherapy delivered intravesically for the treatment of non–muscle-invasive bladder cancer (NMIBC).
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Cretostimogene grenadenorepvec is an investigational targeted immunotherapy that is delivered intravesically. Can you share high-level results with from it?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA updates in urology: December 2025
2
Daniel Spratt, MD, on using ArteraAI to guide salvage therapy decisions
3
The UroOnc Minute: En bloc resection vs TURBT, with Jeremy Y.C. Teoh, MBBS, FRCSEd, FCSHK, FHKAM
4
Top 10 Urology Times bladder cancer articles of 2025
5



















